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Background: Epilepsy is associated with a high disease burden, impacting the lives of
people with epilepsy and their caregivers and family. Persons with medically refractory
epilepsy experience the greatest burden, suffering from profound physical, psychological,
and social consequences. Anecdotal evidence suggests these persons may benefit
from a seizure dog. As the training of a seizure dog is a substantial investment,
their accessibility is limited in the absence of collective reimbursement as is seen
in the Netherlands. Despite sustained interest in seizure dogs, scientific knowledge
on their benefits and costs remains scarce. To substantiate reimbursement decisions
stronger evidence is required. The EPISODE study aims to provide this evidence
by evaluating the effectiveness and cost-effectiveness of seizure dogs in adults with
medically refractory epilepsy.
Methods: The study is designed as a stepped wedge randomized controlled trial that
compares the use of seizure dogs in addition to usual care, with usual care alone. The
study includes adults with epilepsy for whom current treatment options failed to achieve
seizure freedom. Seizure frequency of participants should be at least two seizures per
week, and the seizures should be associated with a high risk of injury or dysfunction.
During the 3 year follow-up period, participants receive a seizure dog in a randomized
order. Outcomemeasures are taken at multiple time points both before and after receiving
the seizure dog. Seizure frequency is the primary outcome of the study and will be
Wester et al. EPISODE: The Study Protocol
recorded continuously using a seizure diary. Questionnaires measuring seizure severity,
quality of life, well-being, resource use, productivity, social participation, and caregiver
burden will be completed at baseline and every 3 months thereafter. The study is
designed to include a minimum of 25 participants.
Discussion: This protocol describes the first randomized controlled trial on seizure
dogs. The study will provide comprehensive data on the effectiveness and cost-
effectiveness of seizure dogs in adults with medically refractory epilepsy. Broader benefits
of seizure dogs for persons with epilepsy and their caregivers are taken into account,
as well as the welfare of the dogs. The findings of the study can be used to inform
decision-makers on the reimbursement of seizure dogs.
Keywords: seizure dog, refractory epilepsy, stepped wedge randomized controlled trial, economic evaluation,
study protocol
INTRODUCTION
Epilepsy is a common neurological disorder, affecting ∼50
million people worldwide (1, 2). The disorder is characterized
by recurrent unprovoked seizures which, for most persons, can
be controlled with antiepileptic drug (AED) regimens. In about
one third of the persons with epilepsy (PWE), seizure freedom
is not achieved despite the use of multiple AED regimens at
therapeutic dosage (3). These persons are considered to have
medically refractory epilepsy (4). Resective surgery may be a
treatment option for persons with medically refractory epilepsy.
However, only about half of PWE meets the strict eligibility
criteria, and about 50% of procedures does not result in sustained
seizure freedom (5, 6). Neurostimulation has offered new
treatment options in medically refractory epilepsy with vagus
nerve stimulation and deep brain stimulation, however, these
advances seldomly result in seizure freedom (7, 8). Consequently,
a group of persons continues to face the challenges of living with
persistent seizures.
Burden of Medically Refractory Epilepsy
Seizures are associated with several risks, leading to increased
rates of mortality (9–12) and morbidity (13, 14) in PWE.
Causes for excess mortality include status epilepticus and seizure-
related accidents (12, 15, 16). However, the most important
contributor of excess mortality is sudden unexpected death in
epilepsy (SUDEP) (17–20), that is, death occurring without
finding a toxicological or anatomical cause. While rare among
Abbreviations: AED, Antiepileptic drug; BMA, Bultersmekke assistancedogs;
EEG, Electroencephalography; EPISODE, Epilepsy support dog evaluation;
EPOC, Effective practice and organization of care; EQ-5D-5L, EuroQol 5
dimensions 5 level questionnaire; EQ-VAS, EuroQol visual analogue scale;
GEE, Generalized estimated equations; GLMM, Generalized linear mixed model;
HN, Hulphond Nederland; ICECAP-A, ICEpop CAPability measure for Adults;
ICER, Incremental cost-effectiveness ratio; iMCQ, iMTA Medical Consumption
Questionnaire; iMTA, institute for Medical Technology Assessment; iPCQ, iMTA
Productivity Costs Questionnaire; iVICQ, iMTA Valuation of Informal Care
Questionnaire; NHS-3, National Hospital Seizure Severity Scale; PWE, Person(s)
with epilepsy; QALY, Quality-adjusted-life-year; QOLIE-31-P, Quality of Life in
Epilepsy Questionnaire; SEIN, Stichting Epilepsie Instellingen Nederland; SUDEP,
Sudden unexpected death in epilepsy.
persons with new-onset epilepsy, seizure-related deaths may
account for up to 40% of all deaths in persons with medically
refractory epilepsy (15, 21, 22). PWE on average have a lower
quality of life, for instance due to medication side-effects and
seizure-related injuries. Psychological distress is also a common
concern in epilepsy, with PWE being twice as likely to report
depression and anxiety compared to the general population (23,
24). While persons with medically refractory epilepsy represent
the minority of PWE, they account for most of the disease burden
of epilepsy (25).
In addition to the health impact, medically refractory epilepsy
comes with restrictions in several life domains including housing,
education, occupation, transportation, and role expectations. As
a consequence, PWE might feel restricted in their social life
and independence as they generally rely heavily on informal
care or community services. Finally, it is widely acknowledged
that refractory epilepsy can be considered a cost-intensive
disorder, with estimates of the indirect costs (productivity and
informal care-related costs) generally exceeding the direct costs
(treatment-related costs) (26, 27). As such, medically refractory
epilepsy imposes a burden not only on PWE, but also on their
families and on society as a whole (28, 29).
Seizure Dogs
The seemingly unpredictable nature of seizures is often
considered to be the most disabling aspect of the disorder.
Timely detection therefore is essential and can reduce the risks
that accompany seizures through early intervention. This has
caused PWE and researchers to seek out tools that can help with
detecting seizures and/or alarming caregivers during seizures.
Technological solutions so far have not been able to recognize all
types of seizures (30), which may explain the sustained interest
in seizure dogs. Seizure dogs can be trained to detect a variety of
seizure types, as they are aware of changes in body movements
as well as physiological signals. Furthermore, seizure dogs are
able to interact with the PWE in an active way and can recognize
seizures based on the observed level of awareness. An additional
benefit is that seizure dogs are trained to act upon a seizure
by showing a specific response during or immediately after the
seizure. This way, seizure dogs may enable timely intervention
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which can help reduce subsequent seizures and physical risks.
Exploratory studies on seizure dogs have shown a reduction in
seizure frequency and improvements in quality of life of the
PWE (31–36), indicating that persons with medically refractory
epilepsy benefit from the companionship of a seizure dog.
While patient organizations and media have shown a
sustained interest in seizure dogs over the last decade, the topic
remains poorly investigated. Previous studies assessing seizure
dogs were mainly retrospective, anecdotal reports with the risk of
substantial reporting bias (31–34, 36). The definition of a seizure
dog varied across these studies, with some studies including
untrained (pet) dogs. Further limitations were limited or no
verification of the epilepsy diagnosis and lacking control groups.
The only prospective study was conducted by Strong et al.
(35), following 10 PWE in a non-randomized design. While
the study suggests seizure dogs may reduce seizure frequency,
no prospective studies substantiating this expectation have been
published. Yet, recent reviews acknowledge the need for further
evidence to support the effectiveness of seizure dogs (37, 38).
Political Rationale for a Study on Seizure
Dogs in the Netherlands
One of the consequences of the scarce evidence in this field
is that seizure dogs are not reimbursed in most countries. To
substantiate reimbursement decisions, decision-makers require
evidence of effectiveness and safety, with randomized controlled
trials generally being the preferred study design. Additional
evidence requirements may apply, such as cost-effectiveness
data being a prerequisite for instance in The Netherlands and
in The United Kingdom. Without collective reimbursement
the accessibility of seizure dogs is limited, as is seen in
The Netherlands where PWE generally rely on out-of-pocket
payment, donations, or crowdfunding. Affordability issues
alongside encouraging anecdotal reports of PWE who privately
financed a seizure dog have brought the reimbursement issue
to the attention of the Dutch healthcare authorities. As the
current evidence base was found to be insufficient to support a
positive reimbursement decision (39), the EPISODE (EPIlepsy
SuppOrt Dog Evaluation) study was commissioned to inform
decision-makers on the reimbursement of seizure dogs in the
Netherlands (40).
This protocol describes the EPISODE study which aims to
evaluate the effectiveness and cost-effectiveness of seizure dogs
combined with usual care in comparison with usual care only in
adults with medically refractory epilepsy.
METHODS AND ANALYSIS
Study Design
The study is designed as a prospective stepped wedge randomized
controlled trial (41, 42), where randomization occurs at the
individual level. In this design, all participants begin in the
control phase and sequentially move to the intervention phase
in a randomized order. This design was chosen because it allows
for rollout of the intervention to all participants. In the case
of a standard randomized controlled trial the risk of drop-out
during the 3 year follow-up was anticipated to be substantial
among those randomized to the control group, especially as
blinding of the participants would be impossible. An additional
advantage of the stepped wedge design is that it allows for
staged implementation, which was inevitable in the context of
the current study because the intervention involves intensive
selection and training of dogs. The current capacity of the
assistance dog schools participating in the EPISODE study would
not permit simultaneous rollout of the required number of
seizure dogs to all participants.
Data collection started in June 2019 and will take 3 years
to complete. To evaluate the effectiveness and cost-effectiveness
of seizure dogs, all outcome measures will be taken at multiple
time points both before and after the allocation of participants to
the intervention.
Participants
The study population consists of adult persons with medically
refractory epilepsy who experience persistent seizures despite
currently available treatment options. The seizures should be
associated with a high risk of injury or dysfunction. In addition,
the welfare of the dog has to be ensured. Inclusion and exclusion
criteria are presented in Table 1.
Recruitment and Inclusion
Clinical experts at the academic center for epileptology
(Kempenhaeghe) and the expertise center for epilepsy and sleep
medicine (SEIN) will inform PWE fulfilling the inclusion criteria
about the study. In addition, the assistance dog schools, the Dutch
Epilepsy Foundation, and the Dutch Epilepsy Association will
bring the study to the attention of PWE by promoting the study
through their communication channels (e.g., newsletter, social
media, events).
The inclusion process consists of three phases. First, the PWE
gives informed consent and hands in an eligibility statement from
their treating neurologist. Subsequently, a neurologist from the
study team double-checks eligibility based on the medical file and
reaches out to the treating neurologist when needed. Finally, the
assistance dog school pays a visit to the person’s home to assess
the suitability of the living situation and the support network of
the PWE.
Intervention
Seizure dogs are trained to detect seizures and to respond during
or immediately after a seizure. Different seizure types require
different responses. Responses include, but are not limited to:
summoning help by the activation of an alarm system or warning
someone, helping the PWE to a safe place or position during or
after a seizure, blocking the PWE during episodes of reduced
awareness from walking into obstacles or dangerous areas (e.g.,
crossing the street), and providing comfort/emotional support
to the PWE until the seizure subsides. The specific set of tasks
is tailored to the individual, taking into account the PWE’s
seizure characteristics, capabilities, support network and living
environment. There are reports of dogs that allegedly anticipate
on impending seizures and provide a warning signal. However,
research to confirm the innate seizure-alerting abilities of dogs
has been inconclusive and the presence of this behavior cannot
be guaranteed or trained by assistance dog schools.
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TABLE 1 | Inclusion criteria.
Inclusion criteria Exclusion criteria
• Aged 18 years or older;
• Confirmed diagnosis of epilepsy by a neurologist with video or electroencephalographic
(EEG) confirmation;
• Failure of adequate trials of two tolerated, appropriately chosen and used AED regimen to
achieve sustained seizure freedom (i.e., medically refractory epilepsy);
• Not eligible for resective surgery, not prepared to accept the risks of resective surgery, or
resective surgery has not resulted in seizure freedom;
• Prepared not to commence with a ketogenic diet during the study period;
• Minimum of 2 seizures per week on average over the last 6 monthsa;
• High risk of injury or dysfunction due to seizures associated with reduced awareness and/or
a loss of balance;
• Seizures are not preceded by a warning signal that allows the PWE to act on the impending
seizure;
• Capacity to take care of the dog and back-up support in the environment of the PWE to
temporarily take over the care of the dog if necessary;
• Adequacy to fill in questionnaires and seizure diaries, either alone or with the support of
a caregiver.
• Predominance of psychogenic non-epileptic seizures;
• Institutionalized in a 24/7 care home;
• Currently in possession of a trained (either active or retired)
seizure dog;
• A planned epilepsy surgery, deep brain simulation surgery, or
vagus nerve stimulation surgery within the trial duration;
• Disabilities that would require additional, non-seizure related
assistance dog tasks (e.g., dependence on a wheelchair).
aAll types of epileptic seizures may be included in the seizure count. However, given the further criteria (e.g., high risk of injury and/or dysfunction), PWE with tonic-clonic seizures, tonic
seizures, clonic seizures, atonic seizures, and/or some focal dyscognitive seizures are most likely to be included in the study.
As the training of seizure dogs is time intensive, two
assistance dog schools have been selected to deliver the training
program for the seizure dogs that participate in the study:
Hulphond Nederland (HN) and Bultersmekke Assistancedogs
(BMA). Participants will receive a seizure dog from the school
of their preference, striving for an equal balance between the
schools. Both schools adhere to the standards of Assistance Dogs
International for the training of seizure dogs and use the same
endpoints for qualification. The schools, however, use different
training protocols. At HN, the dog is trained in a host family and
in a kennel before moving in with the PWE at an age of ∼20
months. The training of BMA takes place entirely at the PWE’s
home, starting when the dog is∼8 weeks old. In both schools the
training of a seizure dog takes around 24 months to complete.
The training consists of ∼1 year of basic assistance dog training
(i.e., simple commands and socialization) followed by ∼1 year
of epilepsy-specific training, whereby the focus is on recognizing
and responding to seizures. The detailed training schedules of
both assistance dog schools can be found in Supplement 1.
Participants will continue to receive care as usual during the
intervention phase next to having the seizure dog. Participants
can keep their seizure dog after the study has ended.
Comparator
Participants in the control phase will receive usual care without
a seizure dog. Usual care consists of AED treatment, which
may be complemented by vagus nerve stimulation and/or deep
brain stimulation. Some participants might use detection and
alarm devices in addition to their treatment. These devices
are not commonly reimbursed in the Netherlands, but can be
purchased privately.
Best Medical Practice
Participants will continue to get best medical practice for the
entire study duration. Hence, changes in AED regimen or in the
settings of the vagus nerve stimulator or the deep brain stimulator
are allowed. Treatment details and the use of detection and alarm




The primary outcome of this study is seizure frequency,measured
per 28 days. The frequency of seizures is an important indicator
for the severity of epilepsy and is therefore one of the most widely
used outcomes in the literature on seizure dogs (31–36). The
knowledge that the dog will be present and is able to respond
during a seizure can be reassuring for PWE, which may reduce
seizure worry and stress. As stress is known to be an important
trigger for seizures (43, 44), the response function of the dog is
expected to result in a decreased seizure frequency. Moreover,
as the dog will be trained to warn someone, this may result
in administering rescue medication on time and decreasing the
likelihood of sequential seizures. Hence, it is theorized that the
companionship of a seizure dog will reduce seizure frequency. As
the mechanism through which the seizure dog reduces seizure
frequency is unknown, we work with a simplified causal model
(Figure 1).
Secondary Outcome Measures
In addition to the effect of seizure dogs on seizure frequency,
the seizure dog might be beneficial for a broader range of
outcomes. Focusing only on seizure frequency might therefore
underestimate the full effect of seizure dogs, especially since not
much is known about the mechanisms by which seizure dogs
might impact the PWE’s health. Therefore, additional measures
of health outcomes (such as quality of life) will be administered
through questionnaires. Furthermore, the seizure dog might
prove beneficial to PWE beyond their health. To capture the
broader individual and societal benefits of seizure dogs, data will
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FIGURE 1 | Theorized relationship between the response function of a seizure
dog and seizure frequency.
be collected on well-being, productivity, resource use, and social
participation (38). Finally, as the seizure dog may have an impact
on the burden of providing informal care to PWE, the PWE’s
primary caregiver will be invited to fill in questionnaires as well.
Table 2 provides an overview of all the outcome measures that
will be administered during the study. All questionnaires will be
administered in Dutch.
Randomization Procedure
Due to the difference in training protocols, participants can only
be randomized within their assistance dog school group (i.e.,
BMA or HN). Hence, stratified randomization will be applied.
In the BMA group, the randomization determines the start of
the 2 month period in which the participant receives a puppy
at home and begins with the basic assistance dog training. The
randomization in the HN group determines the start of the 3
month period in which the participant receives a trained dog at
home and continues the epilepsy-specific training. The stepped
wedge schedule is designed bearing in mind that all participants
have a qualified seizure dog before the end of the study, while
considering the capacity of the training schools. In addition,
the schedule allows for a minimum of three measurements
before and three measurements after the intervention for each
participant with respect to the primary outcome measure, in line
with the Effective Practice and Organization of Care (EPOC)
guidelines (52). In the BMA group, this resulted in two allocation
slots meaning that multiple participants receive a puppy within
the same period. In the HN group, participants were randomized
over 13 allocation slots, as trained dogs will become available one
at a time. The stepped wedge schedules are shown in Figure 2.
A good match with the PWE is important for the seizure
dog to function effectively. Participants in the BMA group will
therefore select their own puppy with the guidance of BMA,
i.e., a puppy that appears to be a good match with the PWE
and seems suitable for assistance dog tasks. In the HN group,
participants receive a dog that is available at that moment, i.e., a
dog that has finished the basic assistance dog training, is found
to be suitable for seizure dog tasks, and appears to be a good
match with the PWE. While the randomization determines the
order in which participants receive a seizure dog, it might occur
that the allocated dog in the HN group does not match with the
PWE (e.g., in terms of energy level, living situation, or support
network). In that case, the participant switches places with the
next participant in the randomized allocation sequence.
Data Collection
Seizure frequency will be recorded continuously using a
paper seizure diary for the duration of the study (36 months).
On days when the participant experiences at least one seizure,
participants are asked to record seizure-related injuries and the
use of rescue medication or a magnet (when the PWE has a vagus
nerve stimulator) to achieve seizure cessation. After receiving a
puppy (in the BMA group) or dog (in theHN group), participants
are also asked to record whether the dog appears to show
responding and/or alerting behavior. Amobile phone application
will be used to remind participants to fill in their seizure diary. In
order to monitor non-response and to limit retrospective entry
of seizures, the application will ask participants weekly to upload
a photo of their seizure diary. Non-response will be acted on
when observed by the daily study coordinator, by contacting the
participant through e-mail or phone. The secondary outcome
measures will be collected at baseline and every 3 months
thereafter, using paper questionnaires.
The cut-off point between control measurements and
intervention measurements is determined prior to the analysis,
based on the expected ability of the dog to perform seizure-
related tasks at the PWEs home. This is described hereafter.
Sample Size Calculation
The sample size calculation was based on the primary outcome of
seizure frequency per 28 days. To determine the required sample
size of the study, a simulation-based approach was adopted, using
a generalized linear mixed-effects model with subject-specific
random-intercepts, including a term for the time on intervention
to allow for a change in treatment effect over time. The advantage
of a simulation-based approach is that it can consider the specific
features of the study including the repeated measurements and
the envisioned stepped wedge schedule (53). Estimates of the
treatment effect (i.e., time on treatment) were derived from a
study by Strong et al. (35). In that study the mean number of
seizures in each 4 week period decreased from 13.8 in weeks 1–12
(baseline) to 9.73 in weeks 13–24 (training) to 8.8 in weeks 25–36
(follow-up) and to 8.0 in weeks 37–48 (follow-up). Four different
assumptions were used with respect to the timing of the expected
decrease in seizure frequency, in line with the analysis plan in
Supplement 2. The study power was calculated as the proportion
among 2,500 simulation runs that detects the intervention effect
at a 5% significance level. The calculation was run for two sample
sizes: 20 and 25 participants. The sample size calculation showed
that with both sample sizes, the study would detect the effect on
seizure frequency per 28 days as observed by Strong et al. (35)
regardless of the assumptions with respect to the timing of the
expected decrease in seizure frequency (i.e., the power was higher
than the pre-specified threshold of 0.8 in all scenarios). The study
will be designed to include a minimum of 25 participants to
account for drop-outs.
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TABLE 2 | Overview of outcome measures.





Demographic information (e.g., age, gender, education, living
situation).
Structured questionnaire X X
Disease and treatment characteristics (e.g., seizure characteristics,
age at diagnosis, epilepsy treatment history, current epilepsy
treatment, use of detection devices, comorbidities).
Structured questionnaire X
HEALTH
Seizure frequency (per seizure type). Seizure diary X
Seizure-related injuries (categorized as light, mild or severe, and
use of rescue medication/magnets to achieve seizure cessation).
Seizure diary X
Seizure severity in terms of (post)ictal phenomena, postictal
duration, automatisms, functional impairment, injuries, and
warnings.
Dutch translation and adaptation of the NHS-3 (45) X
Epilepsy-specific quality of life in terms of seizure worry, emotional
well-being, energy/fatigue, cognition, medication side-effects,
social function, and overall quality of life.
QOLIE-31-P (46) X
Generic quality of life in terms of mobility, self-care, usual activities,
pain/discomfort, anxiety/depression, and overall quality of life.
EQ-5D-5L and EQ-VAS (47) X X
WELL-BEING




Utilization of healthcare in terms of events (e.g., emergency
department visits, ambulance calls, hospitalizations) and total
healthcare costs including informal care.
iMCQ (49) X
PRODUCTIVITY
Employment, absenteeism (days missed from work), presenteeism
(reduced productivity at work), and unpaid work.
iPCQ (50) X
SOCIAL PARTICIPATION
Participation in household activities, social contact, role
expectations, societal participation, and leisure activities.
Structured questionnaire X X
CAREGIVER BURDEN
Objective burden (e.g., duration and intensity), subjective burden




Performance of response tasks during or after the seizure (e.g.,
activation of alarm system, bringing medication, blocking the PWE)
and observations of alerting behavior (e.g., warn prior to seizure).
Seizure diary X
NHS-3, National Hospital Seizure Severity Scale; QOLIE-31-P, Patient-Weighted Quality of Life in Epilepsy Inventory-31; EQ-5D-5L, EuroQol 5-Dimensions 5-Levels Questionnaire; EQ-
VAS, Euroqol Visual Analoque Scale; ICECAP-A, ICEpop CAPability measure for Adults; iMCQ, iMTA Medical Consumption Questionnaire; iPCQ, iMTA Productivity Costs Questionnaire;
iVICQ, iMTA Valuation of Informal Care Questionnaire.
Analysis
Effectiveness Analysis
The effectiveness of seizure dogs will be measured in terms of
reduced seizure frequency. All types of epileptic seizures will
be included in the main analysis. Data will be described using
summary statistics and scatterplots of the time series, in order
to identify any underlying trends of seizure frequency, seasonal
patterns and outliers.
Generalized linear mixed models (GLMM) or generalized
estimated equations (GEE) are deemed as appropriate statistical
methods to analyze data from stepped wedge studies (41, 42).
As the primary endpoint concerns count data, a GLMM Poisson
model with a logarithmic link is deemed most appropriate. The
main model will include a term for time on intervention to allow
for a gradual change in effect of treatment over time.
The intervention phase consists of two distinct stages: the
development stage during which the dog is taught epilepsy-
specific tasks at the participant’s home, and the period after
the dog finished the epilepsy-specific training and is officially
certified as “seizure dog.” The cut-off point between the control
and intervention period relates to the expected moment at which
the dog has the ability to perform seizure-related tasks at the
PWEs home. For participants in the HN group, we expect the
effect to occur with a delay of 6 months after the dog moves
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FIGURE 2 | Stepped wedge schedule.
from the kennel to the participant’s home to account for the
period of acclimatization. For participants in the BMA group we
expect a decrease in seizure frequency as soon as the epilepsy-
specific training starts, as the acclimatization period already took
place during the basic assistance dog training at the participant’s
home. Hence, for PWE in the BMA group the start of the
intervention phase (i.e., time on intervention) is defined as the
start of the epilepsy-specific training at the participant’s home.
More details on the classification of “control” and “intervention”
measurements can be found in the analysis plan (Supplement 2).
While seizure clusters are common in refractory epilepsy,
there is no agreement on the definition of a cluster. This lack
of consensus is revealed in the literature, where definitions that
have been referenced range from episodes of multiple seizures
within minutes to up to 24 h (54, 55). This study only allows us
to group seizure clusters that occur within a given day, as there
is no additional granularity in the measurement of time in the
seizure diary.
GLMM will be used for the secondary endpoints as well,
however, the type of model (Normal, Binomial, Poisson)
will be determined by the type of data for each outcome.
Conclusions will be drawn from this main analysis on primary
and secondary endpoints.
Given the uncertainty surrounding the model assumptions,
sensitivity analyses will be conducted to test the implications
of the most important choices, such as the starting point of
the intervention phase, the inclusion of a main effect, the types
of seizures included in the count data and the definition of
seizure clusters.
In addition, exploratory analysis will be performed to gain
insight into the relationship between the dogs responding and/or
alerting behavior and the PWE’s health outcomes (e.g., seizure
frequency, seizure-related injuries, anxiety).
Cost-Effectiveness Analysis
The cost-effectiveness analysis will follow the Dutch guidelines
for economic evaluations in healthcare (56). In line with this
guideline, the cost-effectiveness analysis will adopt a societal
perspective. This implies that the analysis will take into account
all costs within the health care sector, patient and family costs
(i.e., time costs of informal caregivers and travel costs) and costs
in other sectors (i.e., productivity costs). The Dutch costing
manual will be used to derive unit costs (57). The intervention
costs include the purchase of a puppy, the costs of the training
program and follow-up services, and costs for keeping the dog
until the dog retires.
The main outcome of the analysis are the incremental costs
per quality-adjusted life-year (QALY) gained, expressed as the
incremental cost-effectiveness ratio (ICER). The main analysis
will use a lifetime time horizon. Lifetime costs and effects will
be estimated, assuming that the dogs will be replaced at the time
they retire. Future costs and effects will be discounted according
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to the Dutch guidelines for economic evaluations in healthcare.
Scenario analyses will explore the cost-effectiveness of seizure
dogs without the assumption that dogs will be replaced when they
retire. Additional uncertainties (both structural and parameter)
will be tested in scenario- and sensitivity analyses.
Ensuring the Dog’s Welfare
The current animal welfare debate has demonstrated broad
acknowledgment that interventions with assistance dogs may
raise welfare concerns for participating animals (58, 59). BMA
and HN apply internal protocols to monitor the health of
seizure dogs and the conditions in which the seizure dogs
function, in line with international standards (Assistance Dogs
International). Before PWE enter the study, information is
provided to the PWE in order to make them aware of the
impact of taking care of a dog. Adequacy to ensure the dogs
welfare is a criterion for participating in the study. After
the dog is placed at the participant’s home, the welfare of
the dog will be monitored regularly by the assistance dogs
schools. The Institute for Anthrozoology will conduct a side-
study to evaluate the welfare of the seizure dogs involved in the
current study.
DISCUSSION
This study is the first randomized controlled trial concerning
the effectiveness and cost-effectiveness of seizure dogs. The
stepped wedge trial design combined with a 3 year follow-
up, and the broad range of outcomes measured, allow for
a thorough investigation of the clinical and societal benefits
of this intervention. For instance, the study will look beyond
health-outcomes, taking into account PWE and caregivers’ well-
being as well as their participation in social activities. Another
neglected outcome in previous studies was the economic benefit
of seizure dogs. While the costs of the training program may
be considerable, and for some PWE insurmountable when not
covered by health insurance, the cost savings due to reduced
medical consumption, a reduced informal caregiver burden and
increased productivity might compensate this investment. As
we will apply a societal perspective, these potential benefits are
accounted for in the cost-effectiveness analysis, capturing the full
range of expected costs and benefits attributable to seizure dogs
to both PWE and society.
Limitations and Complications
Some limitations in the design of the study deserve mentioning.
The study relies on self-reported outcome measures which,
particularly in the light of the non-blinded design, have the
potential of introducing reporting bias. The incentives to
misrepresent responses are expected to be mitigated by several
factors. First, participants can keep their dog after the study has
ended, independent of the outcome of the study. As a result,
the incentive to bias the results in order to increase the chance
of keeping the dog will be removed. Second, participants often
use the seizure diary of the study also to inform their treating
neurologist. Hence, misrepresenting well-being in the seizure
diary would result in misinforming ones treating neurologist as
well. Third, participants have agreed that the neurologists from
the study team may access their medical record for validation
purposes. Finally, the analyses plan differentiates between the
intervention period and the training period, and participants are
neither aware of these differences nor can forecast the impact of
changing responses in different phases of the study, limiting the
impact of strategic responses. Nevertheless, strategic responses
may not all be avoided.
Another limitation is that the study design does not allow
for a comparison of the benefits of an untrained dog and a
trained seizure dog. It has been suggested in the literature that pet
ownership at itself may have beneficial effects on their handler’s
health and well-being (60–63). However, it was not feasible to
include a control arm in which participants are assigned to
receiving an untrained pet dog. Most importantly, there were
concerns for the well-being of the participant and the dog, given
the various instinctive ways in which the dog may react to
seizures in their human companion when they are not trained
which may include aggressive or escape behavior (64). Adding
to this, it was expected that very few eligible PWE were willing to
enroll in the study when they knew they could be randomized to
receiving an untrained pet dog.
A third limitation is that the allocation schedule for the
BMA group resulted in only two allocation slots. As a
consequence, factors that might influence the results (apart from
the intervention) might be less well-balanced over “control” and
“intervention.” However, given that the data of the BMA and HN
group will be pooled, the impact on the results will be limited.
Some remarks should also be made with respect to the
focus of the current study. The current study investigates
effectiveness without a full understanding of the mechanism
through which seizure dogs reduce seizure frequency as was
observed in previous studies. However, the political relevance
of the effectiveness and cost-effectiveness question is believed
to surpass the uncertainty regarding the mode of action and
hence it is warranted to measure effectiveness regardless of
a clear understanding of how the effect arises. Exploratory
analysis (e.g., on the relationship between response/alert behavior
and seizure frequency) will be conducted to test hypotheses
concerning the mode of action. In addition, it should be
noted that the study focuses on seizure dogs that are trained
for their response behavior, as training methods for alerting
behavior rely on hypothesized cues by dogs (e.g., variations
in behavior, scent, heart rate) and cannot be guaranteed
in the way that conventional training (i.e., seizure response
training) can. Nevertheless, the number of seizures, which will
be the primary outcome of the study, might be influenced
by both response and alerting behavior. Finally, this study is
not designed to evaluate adverse events as data on the type
and number of potential adverse events are not registered
in a systematic way. However, several processes are in place
to optimize the safety of the PWE as well as the dog (e.g.,
careful selection and thorough training of the dogs as well as
regular home visits by the assistance dogs schools), making
adverse events seem unlikely. If major concerns regarding
patient- or dog safety occur, the dog will be removed from
the PWE’s home after careful consideration, with or without
assigning a replacement dog. These serious adverse events will
be recorded by the study team, and described as part of the study
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results. Aspects of safety that influence a participant’s well-being,
quality of life or resource use will be measured throughout
the study.
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